

# Long-term Clinical Outcomes and Biomarker Analyses of With Metastatic Triple-Negative Breast Cancer

JAMA Oncology

5, 74

DOI: [10.1001/jamaoncol.2018.4224](https://doi.org/10.1001/jamaoncol.2018.4224)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2108-2121.	13.9	3,097
2	Immunotherapy in Breast Cancer: the New Frontier. <i>Current Breast Cancer Reports</i> , 2018, 10, 35-40.	0.5	19
4	&lt;p&gt;Triple-negative breast cancer: current perspective on the evolving therapeutic landscape&lt;/p&gt;. <i>International Journal of Women's Health</i> , 2019, Volume 11, 431-437.	1.1	117
5	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, <i>Research Directions. JNCI Cancer Spectrum</i> , 2019, 3, prz049.	1.4	11
6	Pregnancy and Breast Cancer: Pathways to Understand Risk and Prevention. <i>Trends in Molecular Medicine</i> , 2019, 25, 866-881.	3.5	54
7	Targeting PD-1 in cancer: Biological insights with a focus on breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 35-43.	2.0	18
9	Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. , 2019, 7, 165.		135
10	PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review. <i>Cancers</i> , 2019, 11, 1033.	1.7	160
11	Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130). <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 1083-1091.	0.6	32
12	Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 34.	2.3	55
13	Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: A comprehensive systematic review. <i>Oncology Reviews</i> , 2019, 13, 425.	0.8	14
14	Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: A systematic review and meta-analysis. <i>Cancer Medicine</i> , 2019, 8, 7503-7515.	1.3	35
15	If we build it they will come: targeting the immune response to breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 37.	2.3	132
16	Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 119.	2.2	21
17	Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab. , 2019, 7, 274.		26
18	Lack of Robust Prognostic Biomarkers for Immunotherapy in Breast Cancer's Adverse Events. <i>JAMA Oncology</i> , 2019, 5, 1639.	3.4	1
19	Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling. <i>Scientific Reports</i> , 2019, 9, 13125.	1.6	44
20	Combining Radiation Therapy with Immune Checkpoint Blockade in Breast Cancer. <i>Current Breast Cancer Reports</i> , 2019, 11, 203-216.	0.5	2

#	ARTICLE	IF	CITATIONS
21	Precision medicine for locally advanced breast cancer: frontiers and challenges in Latin America. <i>Ecancermedalscience</i> , 2019, 13, 896.	0.6	8
22	Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. <i>Gynecologic Oncology</i> , 2019, 154, 314-322.	0.6	101
23	Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer. <i>Cancer Discovery</i> , 2019, 9, 1208-1227.	7.7	81
24	Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data. <i>Clinical Cancer Research</i> , 2019, 25, 5717-5726.	3.2	71
25	Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019, 193, 105415.	1.2	44
26	DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy. <i>Journal of Oncology</i> , 2019, 2019, 1-14.	0.6	18
27	Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1 <sup>+</sup> triple negative breast cancer cells. <i>Oncolmunology</i> , 2019, 8, e1624128.	2.1	37
28	<i>In silico</i> simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model. <i>Royal Society Open Science</i> , 2019, 6, 190366.	1.1	54
29	Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 1132.	3.4	285
30	Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node- <sup>+</sup> positive study. <i>European Journal of Cancer</i> , 2019, 114, 76-88.	1.3	37
31	The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 4644-4655.	3.2	76
32	Recent advances in triple negative breast cancer: the immunotherapy era. <i>BMC Medicine</i> , 2019, 17, 90.	2.3	267
33	IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. <i>Future Oncology</i> , 2019, 15, 1951-1961.	1.1	58
34	Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. <i>Nature Medicine</i> , 2019, 25, 920-928.	15.2	589
35	A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. <i>Annals of Oncology</i> , 2019, 30, 1279-1288.	0.6	438
36	Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 399-400.	12.5	44
37	Targeting the PI3-kinase pathway in triple-negative breast cancer. <i>Annals of Oncology</i> , 2019, 30, 1051-1060.	0.6	180
38	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials. <i>JAMA Oncology</i> , 2019, 5, 1008.	3.4	526

#	ARTICLE	IF	CITATIONS
39	Immune checkpoint inhibitors: a potential treatment breakthrough for metastatic triple-negative breast cancer?. <i>Women's Health Investigation</i> , 2019, 2, 2-2.	0.0	0
40	Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy. <i>Cancer Letters</i> , 2019, 452, 66-70.	3.2	150
41	Current Landscape of Immunotherapy in Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 1205.	3.4	260
42	Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade. <i>Clinical Cancer Research</i> , 2020, 26, 1712-1724.	3.2	76
43	JQ1-Loaded Polydopamine Nanoplatfrom Inhibits c-MYC/Programmed Cell Death Ligand 1 to Enhance Photothermal Therapy for Triple-Negative Breast Cancer. <i>ACS Applied Materials &amp; Interfaces</i> , 2019, 11, 46626-46636.	4.0	69
44	Clinical Implications of Extracellular HMGA1 in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5950.	1.8	20
46	Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 151.	2.2	30
47	Immunotherapy in Triple-Negative Breast Cancer: Present and Future. <i>Current Breast Cancer Reports</i> , 2019, 11, 259-271.	0.5	22
48	Atezolizumab for the treatment of triple-negative breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 1-5.	1.9	78
49	Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up. <i>JAMA Oncology</i> , 2019, 5, 334.	3.4	206
50	Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts. <i>Clinical Cancer Research</i> , 2020, 26, 657-668.	3.2	70
51	Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer. <i>Future Oncology</i> , 2020, 16, 4439-4453.	1.1	29
52	&lt;p&gt;Immunotherapy for the Treatment of Breast Cancer: Emerging New Data&lt;p&gt;. <i>Breast Cancer: Targets and Therapy</i> , 2019, Volume 11, 321-328.	1.0	25
53	A phase 2 clinical trialâ€ assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic tripleâ€negative breast cancer. <i>Cancer</i> , 2020, 126, 850-860.	2.0	116
54	New insight in endocrine-related adverse events associated to immune checkpoint blockade. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101370.	2.2	60
55	Breast cancer vaccines: Heeding the lessons of the past to guide a path forward. <i>Cancer Treatment Reviews</i> , 2020, 84, 101947.	3.4	35
56	Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 44-59.	5.1	826
57	Building momentum for subsets of patients with advanced triple-negative breast cancer. <i>Lancet Oncology</i> , The, 2020, 21, 3-5.	5.1	6

#	ARTICLE	IF	CITATIONS
58	Tumor mutation burden, immune checkpoint crosstalk and radiosensitivity in single-cell RNA sequencing data of breast cancer. <i>Radiotherapy and Oncology</i> , 2020, 142, 202-209.	0.3	47
59	Personalized treatment in metastatic triple-negative breast cancer: The outlook in 2020. <i>Breast Journal</i> , 2020, 26, 69-80.	0.4	31
60	&lt;p&gt;Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 9375-9387.	0.9	16
61	Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. <i>Lancet Oncology</i> , The, 2020, 21, 1283-1295.	5.1	213
62	Immune Checkpoint Blockade Improves Chemotherapy in the PyMT Mammary Carcinoma Mouse Model. <i>Frontiers in Oncology</i> , 2020, 10, 1771.	1.3	7
63	Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. <i>Npj Breast Cancer</i> , 2020, 6, 54.	2.3	181
64	Integrating immunotherapy in the (neo)adjuvant setting of early breast cancer. <i>Current Opinion in Oncology</i> , 2020, 32, 575-584.	1.1	5
65	Understanding PD-L1 Testing in Breast Cancer: A Practical Approach. <i>Breast Care</i> , 2020, 15, 481-490.	0.8	34
66	A view on the landscape of breast cancer brain metastases. <i>CNS Oncology</i> , 2020, 9, CNS59.	1.2	4
67	Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer. <i>Nature Communications</i> , 2020, 11, 3584.	5.8	115
68	Immunotherapeutic Approaches in Triple-Negative Breast Cancer: State of the Art and Future Perspectives. <i>International Journal of Breast Cancer</i> , 2020, 2020, 1-9.	0.6	7
69	Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. <i>Nature Cancer</i> , 2020, 1, 1188-1203.	5.7	114
70	Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?. <i>ESMO Open</i> , 2020, 5, e001112.	2.0	30
71	Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer. <i>Cancers</i> , 2020, 12, 3529.	1.7	60
72	Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. <i>Lancet</i> , The, 2020, 396, 1817-1828.	6.3	992
73	Roles for the FCRL6 Immunoreceptor in Tumor Immunology. <i>Frontiers in Immunology</i> , 2020, 11, 575175.	2.2	16
74	Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatmentâ€”Current Progress, Strategy, and Future Perspective. <i>Frontiers in Immunology</i> , 2020, 11, 1508.	2.2	60
75	Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093761.	1.4	78

#	ARTICLE	IF	CITATIONS
76	The efficacy and safety of PD-1/PD-L1 inhibitors in breast cancer: a systematic review and meta-analysis. <i>Translational Cancer Research</i> , 2020, 9, 3804-3818.	0.4	7
77	Different patterns of treatment-related adverse events of programmed cell death-1 and its ligand-1 inhibitors in different cancer types: A meta-analysis and systemic review of clinical trials. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, e160-e178.	0.7	6
78	Independent drug action and its statistical implications for development of combination therapies. <i>Contemporary Clinical Trials</i> , 2020, 98, 106126.	0.8	9
79	Mise en place: toward neoadjuvant chemoimmunotherapy for early triple-negative breast cancer. <i>Annals of Oncology</i> , 2020, 31, 556-557.	0.6	0
80	Local and distant tumor dormancy during early stage breast cancer are associated with the predominance of infiltrating T effector subsets. <i>Breast Cancer Research</i> , 2020, 22, 116.	2.2	11
81	Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges. <i>BioDrugs</i> , 2020, 34, 611-623.	2.2	38
82	Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094092.	1.4	86
83	Current advances in the diagnosis and personalized treatment of breast cancer: lessons from tumor biology. <i>Personalized Medicine</i> , 2020, 17, 399-420.	0.8	7
84	Tissue Immune Profile: A Tool to Predict Response to Neoadjuvant Therapy in Triple Negative Breast Cancer. <i>Cancers</i> , 2020, 12, 2648.	1.7	10
85	Innovative approaches to immunotherapy in breast cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 4536-4540.	0.6	4
86	Beyond Chemotherapies: Recent Strategies in Breast Cancer Treatment. <i>Cancers</i> , 2020, 12, 2634.	1.7	7
88	Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials. <i>Cancers</i> , 2020, 12, 2497.	1.7	17
89	Prognostication of a 13-immune-related-gene signature in patients with early triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 325-334.	1.1	18
90	Immune parameters associated with survival in metaplastic breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 92.	2.2	23
91	Combination of thermally ablative focused ultrasound with gemcitabine controls breast cancer via adaptive immunity. , 2020, 8, e001008.		28
92	Combinatorial Epigenetic and Immunotherapy in Breast Cancer Management: A Literature Review. <i>Epigenomes</i> , 2020, 4, 27.	0.8	6
93	Physical Activity and Breast Cancer Prevention: Possible Role of Immune Mediators. <i>Frontiers in Nutrition</i> , 2020, 7, 557997.	1.6	17
94	Liquid Biopsies to Evaluate Immunogenicity of Gynecological/Breast Tumors: On the Way to Blood-Based Biomarkers for Immunotherapies. <i>Breast Care</i> , 2020, 15, 470-480.	0.8	11

#	ARTICLE	IF	CITATIONS
95	Clinical Data on Immunotherapy in Breast Cancer. <i>Breast Care</i> , 2020, 15, 450-469.	0.8	12
96	The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy. <i>Vaccines</i> , 2020, 8, 203.	2.1	38
97	Lessons learned at SABCS 2019 and to-dos from immunotherapy in breast cancer. <i>ESMO Open</i> , 2020, 5, e000688.	2.0	0
98	Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 227-241.	0.4	24
99	PD-L1 expression on tumor or stromal cells of nodal cytotoxic T-cell lymphoma: A clinicopathological study of 50 cases. <i>Pathology International</i> , 2020, 70, 513-522.	0.6	4
100	First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 340-348.	0.6	25
101	Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. <i>Npj Breast Cancer</i> , 2020, 6, 15.	2.3	16
102	Atezolizumab in the treatment of metastatic triple-negative breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 981-989.	1.4	20
103	Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors. <i>Immunotherapy</i> , 2020, 12, 675-679.	1.0	3
104	Clinical Development of PD-1/PD-L1 Inhibitors in Breast Cancer: Still a Long Way to Go. <i>Current Treatment Options in Oncology</i> , 2020, 21, 59.	1.3	12
105	Immune Checkpoint Blockade in Patients with Triple-Negative Breast Cancer. <i>Targeted Oncology</i> , 2020, 15, 415-428.	1.7	22
106	Multi-panel immunofluorescence analysis of tumor infiltrating lymphocytes in triple negative breast cancer: Evolution of tumor immune profiles and patient prognosis. <i>PLoS ONE</i> , 2020, 15, e0229955.	1.1	20
107	TNFR2+ TILs are significantly associated with improved survival in triple-negative breast cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1315-1326.	2.0	10
108	Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592090909.	1.4	14
109	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immunology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020, 250, 667-684.	2.1	142
111	2. Therapie des metastasierten Mammakarzinoms. , 2020, , 71-120.		0
112	SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer. <i>Future Oncology</i> , 2020, 16, 1801-1813.	1.1	8
113	Clinical Translation of Nanomedicine and Biomaterials for Cancer Immunotherapy: Progress and Perspectives. <i>Advanced Therapeutics</i> , 2020, 3, 1900215.	1.6	62



#	ARTICLE	IF	CITATIONS
114	Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer?. <i>Translational Oncology</i> , 2020, 13, 100811.	1.7	46
115	The evolving management of metastatic triple negative breast cancer. <i>Seminars in Oncology</i> , 2020, 47, 229-237.	0.8	28
116	The impact of PD-L1â€™N-linked glycosylation on cancer therapy and clinical diagnosis. <i>Journal of Biomedical Science</i> , 2020, 27, 77.	2.6	89
117	Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer. <i>Seminars in Cancer Biology</i> , 2022, 79, 44-57.	4.3	104
118	Quantitative image analysis for CD 8 score in lung small biopsies and cytology cellâ€™blocks. <i>Cytopathology</i> , 2020, 31, 393-401.	0.4	3
119	Landscape of combination therapy trials in breast cancer brain metastasis. <i>International Journal of Cancer</i> , 2020, 147, 1939-1952.	2.3	31
120	Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 59-65.	0.4	13
121	ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 679-686.	0.9	3
122	Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study. <i>World Journal of Surgical Oncology</i> , 2020, 18, 11.	0.8	19
123	Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC. <i>Journal of Clinical Pathology</i> , 2020, 73, 557-562.	1.0	53
124	Hypoxia-sensitive supramolecular nanogels for the cytosolic delivery of ribonuclease A as a breast cancer therapeutic. <i>Journal of Controlled Release</i> , 2020, 320, 83-95.	4.8	54
125	A Phase Ib Study of Preoperative, Locoregional IRX-2 Cytokine Immunotherapy to Prime Immune Responses in Patients with Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1595-1605.	3.2	7
127	Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2â€™negative endocrine-refractory metastatic breast cancer. , 2020, 8, e000173.		62
128	Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1. <i>Chinese Medical Journal</i> , 2020, 133, 853-862.	0.9	21
129	The premise of personalized immunotherapy for cancer dormancy. <i>Oncogene</i> , 2020, 39, 4323-4330.	2.6	17
130	Electrochemical immunoplatform to improve the reliability of breast cancer diagnosis through the simultaneous determination of RANKL and TNF in serum. <i>Sensors and Actuators B: Chemical</i> , 2020, 314, 128096.	4.0	22
131	Molecular subtypes and precision treatment of triple-negative breast cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 499-499.	0.7	64
132	Prospect of immunotherapy in neoadjuvant/adjuvant treatment for early breast cancer. <i>Chinese Clinical Oncology</i> , 2020, 9, 28-28.	0.4	5



#	ARTICLE	IF	CITATIONS
133	&lt;p&gt;Combination Strategies of Checkpoint Immunotherapy in Metastatic Breast Cancer&lt;/p&gt;. OncoTargets and Therapy, 2020, Volume 13, 2657-2666.	1.0	9
134	Immuno-Oncology Biomarkers for Personalized Immunotherapy in Breast Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 162.	1.8	21
135	Development and validation of a stromal immune phenotype classifier for predicting immune activity and prognosis in triple-negative breast cancer. <i>International Journal of Cancer</i> , 2020, 147, 542-553.	2.3	36
136	Current and potential immunohistochemical biomarkers for prognosis and therapeutic stratification of breast carcinoma. <i>Seminars in Cancer Biology</i> , 2021, 72, 114-122.	4.3	27
137	T-cell-based breast cancer immunotherapy. <i>Seminars in Cancer Biology</i> , 2021, 72, 90-101.	4.3	21
138	Progress in systemic therapy for triple-negative breast cancer. <i>Frontiers of Medicine</i> , 2021, 15, 1-10.	1.5	16
139	Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. <i>Cell Research</i> , 2021, 31, 178-186.	5.7	146
140	Pembrolizumab and atezolizumab in triple-negative breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 607-617.	2.0	140
141	A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-1 immunohistochemistry assays for scoring in triple-negative breast cancer. <i>Histopathology</i> , 2021, 78, 567-577.	1.6	23
142	Immunotherapy for early breast cancer: too soon, too superficial, or just right?. <i>Annals of Oncology</i> , 2021, 32, 323-336.	0.6	79
143	Efficacy and safety of pembrolizumab based therapies in triple-negative breast cancer: A systematic review of clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103197.	2.0	7
144	The Multifaceted Role of Regulatory T Cells in Breast Cancer. <i>Annual Review of Cancer Biology</i> , 2021, 5, 291-310.	2.3	24
145	PD-L1 testing based on theÂSP142 antibody in metastatic triple-negative breast cancer: summary of an expert round-table discussion. <i>Future Oncology</i> , 2021, 17, 1209-1218.	1.1	12
146	Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 321-332.	0.6	22
147	Triple-negative breast cancer: new treatment strategies in the era of precision medicine. <i>Science China Life Sciences</i> , 2021, 64, 372-388.	2.3	26
148	Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 85-94.	1.1	15
149	PD-L1 status in breast cancer: Current view and perspectives. <i>Seminars in Cancer Biology</i> , 2021, 72, 146-154.	4.3	69
150	Luminal A breast cancer resistance mechanisms and emerging treatments. , 2021, , 1-22.		2

#	ARTICLE	IF	CITATIONS
151	Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation. <i>Journal of Immunology Research</i> , 2021, 2021, 1-18.	0.9	7
152	Novel Agents for Metastatic Triple-Negative Breast Cancer: Finding the Positive in the Negative. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 109-117.	2.3	10
153	Immunotherapy in Triple-Negative Breast Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2021, 27, 59-66.	1.0	36
154	Decreased levels of circulating cytokines VEGF, TNF- $\beta$ and IL-15 indicate PD-L1 overexpression in tumours of primary breast cancer patients. <i>Scientific Reports</i> , 2021, 11, 1294.	1.6	4
155	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge"(December 4th-5th,) Tj ETQq0 0 0rgBT /Over	1.8	3
157	The evolution and advances of biomarker use in clinical trials for breast cancer treatment—a narrative review. <i>Translational Breast Cancer Research</i> , 0, 2, 6-6.	0.4	0
158	Case Report: Significant Response to the Combination of Lenvatinib and Immune Checkpoint Inhibitor in a Patient With Heavily Pretreated Metastatic Triple Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 582185.	1.3	5
159	Tumor-associated neutrophils activated by tumor-derived CCL20 (C-C motif chemokine ligand 20) promote T cell immunosuppression via programmed death-ligand 1 (PD-L1) in breast cancer. <i>Bioengineered</i> , 2021, 12, 6996-7006.	1.4	20
160	MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	63
161	PD-L1 Protein Expression in Middle Eastern Breast Cancer Predicts Favorable Outcome in Triple-Negative Breast Cancer. <i>Cells</i> , 2021, 10, 229.	1.8	8
162	KCTD12 is a prognostic marker of breast cancer and correlates with tumor immune cell infiltration. <i>Translational Cancer Research</i> , 2021, 10, 261-272.	0.4	1
163	A High-Dimensional Window into the Micro-Environment of Triple Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 316.	1.7	16
164	Interleukin-10: A double-edged sword in breast cancer. <i>Tzu Chi Medical Journal</i> , 2021, 33, 203.	0.4	16
165	Triple-Negative Breast Cancer: Intact Mismatch Repair and Partial Co-Expression of PD-L1 and LAG-3. <i>Frontiers in Immunology</i> , 2021, 12, 561793.	2.2	22
166	Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. <i>Pathology</i> , 2021, 53, 141-156.	0.3	126
167	Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 687-697.	1.1	21
168	Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 2481-2493.	3.2	33
169	Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1005-1016.	3.0	171

#	ARTICLE	IF	CITATIONS
171	Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects. <i>Frontiers in Oncology</i> , 2020, 10, 600573.	1.3	100
172	PD-L1 in Breast Cancer: The Road to the Perfect Biomarker Is Fraught With Uncertainty. <i>Journal of the National Cancer Institute</i> , 2021, 113, 951-952.	3.0	3
173	Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer. , 2021, 9, e002100.		29
174	PD-L1 Expression Is an Independent Marker for Lymph Node Metastasis in Middle Eastern Endometrial Cancer. <i>Diagnostics</i> , 2021, 11, 394.	1.3	2
175	Overview of recent advances in metastatic triple negative breast cancer. <i>World Journal of Clinical Oncology</i> , 2021, 12, 164-182.	0.9	42
176	The role of immunotherapy in metastatic triple negative breast cancer: a narrative review of the current clinical trials. <i>Precision Cancer Medicine</i> , 0, 4, 1-1.	1.8	0
177	The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy. <i>European Journal of Pharmacology</i> , 2021, 895, 173867.	1.7	21
178	Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer. <i>BMC Cancer</i> , 2021, 21, 239.	1.1	28
179	The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 610303.	1.3	118
180	Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer. , 2021, 9, e002022.		40
181	SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1108-1117.	2.1	26
182	Cost-effectiveness Analysis of Atezolizumab Plus Nab-Paclitaxel for Advanced PD-L1 Positive Triple-Negative Breast Cancer in Japan. <i>Clinical Drug Investigation</i> , 2021, 41, 381-389.	1.1	7
183	Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 165-178.	1.1	13
184	Cryoablation and Immunotherapy for Breast Cancer: Overview and Rationale for Combined Therapy. <i>Radiology Imaging Cancer</i> , 2021, 3, e200134.	0.7	25
185	Emerging Therapeutics for Patients with Triple-Negative Breast Cancer. <i>Current Oncology Reports</i> , 2021, 23, 57.	1.8	30
186	Advances in Combining Radiation and Immunotherapy in Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, 143-152.	1.1	24
187	Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review. <i>BMC Cancer</i> , 2021, 21, 425.	1.1	16
188	Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 562315.	1.3	38

#	ARTICLE	IF	CITATIONS
189	Benefit with re-challenge of immune checkpoint inhibitors in patient with metastatic triple-negative breast cancer: a case report. <i>Translational Breast Cancer Research</i> , 2021, 2, 14-14.	0.4	1
190	Immune-related biomarkers in triple-negative breast cancer. <i>Breast Cancer</i> , 2021, 28, 792-805.	1.3	24
191	Microwave ablation induces Th1-type immune response with activation of ICOS pathway in early-stage breast cancer. , 2021, 9, e002343.		31
192	PDL1 expression and its correlation with outcomes in non-metastatic triple-negative breast cancer (TNBC). <i>Ecancermedicalsecience</i> , 2021, 15, 1217.	0.6	10
193	Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 131-147.	1.0	5
194	Construction and Validation of an Immune Infiltration-Related Gene Signature for the Prediction of Prognosis and Therapeutic Response in Breast Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 666137.	2.2	11
195	Pembrolizumab monotherapy in metastatic triple-negative breast cancer. <i>Lancet Oncology</i> , The, 2021, 22, 415-417.	5.1	3
196	Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review. <i>Frontiers in Oncology</i> , 2021, 11, 621639.	1.3	12
197	Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives. <i>Frontiers in Oncology</i> , 2021, 11, 648139.	1.3	18
198	Informing the new developments and future of cancer immunotherapy. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 549-562.	2.7	17
199	The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives. <i>Clinical Immunology</i> , 2021, 226, 108707.	1.4	127
200	Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 519-536.	2.7	56
201	The influence of monoclonal antibodies for cancer treatment on the endocrine system. <i>Postepy Higieny I Medycyny Doswiadczonej</i> , 2021, 75, 317-327.	0.1	0
202	Transferrin Coated <scp>d</scp>-penicillamineâ€“Au-Cu Nanocluster PLGA Nanocomposite Reverses Hypoxia-Induced EMT and MDR of Triple-Negative Breast Cancers. <i>ACS Applied Bio Materials</i> , 2021, 4, 5033-5048.	2.3	8
203	Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study. <i>Clinical Breast Cancer</i> , 2021, 21, 539-551.	1.1	13
204	PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus <i>nab</i>-Paclitaxelâ€“Treated Advanced Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1733-1743.	3.0	83
205	Managing side effects of immune checkpoint inhibitors in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103354.	2.0	15
206	Targeting regulator of G protein signaling 1 in tumor-specific T cells enhances their trafficking to breast cancer. <i>Nature Immunology</i> , 2021, 22, 865-879.	7.0	41

#	ARTICLE	IF	CITATIONS
207	Lovastatin Inhibits EMT and Metastasis of Triple-Negative Breast Cancer Stem Cells Through Dysregulation of Cytoskeleton-Associated Proteins. <i>Frontiers in Oncology</i> , 2021, 11, 656687.	1.3	18
208	Checkpoint inhibitor therapy for metastatic triple-negative breast cancer. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 537-547.	2.7	58
209	Trials of Immunotherapy in Triple Negative Breast Cancer. <i>Current Breast Cancer Reports</i> , 2021, 13, 171-185.	0.5	1
210	PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1274-1281.	2.1	6
211	Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence. <i>Frontiers in Pharmacology</i> , 2021, 12, 653521.	1.6	11
212	Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 681476.	1.3	71
213	CTLA-4 Expression and Its Clinical Significance in Breast Cancer. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2021, 69, 16.	1.0	19
214	Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 658690.	1.3	15
215	Chemotherapy Shifts the Balance in Favor of CD8+ TNFR2+ TILs in Triple-Negative Breast Tumors. <i>Cells</i> , 2021, 10, 1429.	1.8	5
216	Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 945-962.	1.4	26
217	Prognostic prospect of soluble programmed cell death ligand-1 in cancer management. <i>Acta Biochimica Et Biophysica Sinica</i> , 2021, 53, 961-978.	0.9	4
218	Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130. <i>Journal of the National Cancer Institute</i> , 2022, 114, 664-675.	3.0	31
219	Crosstalk between Tumor-Infiltrating Immune Cells and Cancer-Associated Fibroblasts in Tumor Growth and Immunosuppression of Breast Cancer. <i>Journal of Immunology Research</i> , 2021, 2021, 1-15.	0.9	15
220	CX-072 (pacmilimab), a Probody <sup>®</sup> PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study. , 2021, 9, e002447.		26
221	Detachable Liposomes Combined Immunochemotherapy for Enhanced Triple-Negative Breast Cancer Treatment through Reprogramming of Tumor-Associated Macrophages. <i>Nano Letters</i> , 2021, 21, 6031-6041.	4.5	47
222	Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 787-800.	0.9	25
223	Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7154.	1.8	5
224	Independent action models and prediction of combination treatment effects for response rate, duration of response and tumor size change in oncology drug development. <i>Contemporary Clinical Trials</i> , 2021, 106, 106434.	0.8	7

#	ARTICLE	IF	CITATIONS
225	Tumor infiltrating lymphocytes: current pathways to a standard biomarker in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1-3.	1.1	1
226	How low can you go? PD-L1 expression as a biomarker in trials of cancer immunotherapy. <i>Annals of Oncology</i> , 2021, 32, 833-836.	0.6	21
227	A Review of Therapeutic Antibodies in Breast Cancer. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2021, 24, 363-380.	0.9	1
228	TNBC: Potential Targeting of Multiple Receptors for a Therapeutic Breakthrough, Nanomedicine, and Immunotherapy. <i>Biomedicines</i> , 2021, 9, 876.	1.4	41
229	Chemoresistance and Metastasis in Breast Cancer Molecular Mechanisms and Novel Clinical Strategies. <i>Frontiers in Oncology</i> , 2021, 11, 658552.	1.3	30
230	Molecular and Immune Correlates of PDCD1 (PD-1), PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA Methylation in Triple Negative Breast Cancer. <i>Journal of Immunotherapy</i> , 2021, 44, 319-324.	1.2	9
231	Multimodal Intralesional Therapy for Reshaping the Myeloid Compartment of Tumors Resistant to Anti-PD-L1 Therapy via IRF8 Expression. <i>Journal of Immunology</i> , 2021, 207, 1298-1309.	0.4	8
232	Systemic administration of polymersomal oncolytic peptide LTX-315 combining with CpG adjuvant and anti-PD-1 antibody boosts immunotherapy of melanoma. <i>Journal of Controlled Release</i> , 2021, 336, 262-273.	4.8	23
233	Immunotherapy Treatment for Triple Negative Breast Cancer. <i>Pharmaceuticals</i> , 2021, 14, 763.	1.7	30
234	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. , 2021, 9, e002597.		45
235	Breast Cancer Treatments: Updates and New Challenges. <i>Journal of Personalized Medicine</i> , 2021, 11, 808.	1.1	108
236	First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. <i>Annals of Oncology</i> , 2021, 32, 983-993.	0.6	205
237	Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. <i>Annals of Oncology</i> , 2021, 32, 994-1004.	0.6	393
238	Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 83.	2.2	13
239	The Emerging Role of T-Cell Immunoglobulin Mucin-3 in Breast Cancer: A Promising Target For Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 723238.	1.3	5
240	Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies. <i>Pharmaceuticals</i> , 2021, 14, 884.	1.7	17
241	Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development. <i>Expert Opinion on Investigational Drugs</i> , 2021, , 1-15.	1.9	8
242	Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer. <i>Nature Communications</i> , 2021, 12, 5668.	5.8	91



#	ARTICLE	IF	CITATIONS
243	Weekly Paclitaxel given concurrently with Durvalumab has a favorable safety profile in triple-negative metastatic breast cancer. <i>Scientific Reports</i> , 2021, 11, 19154.	1.6	17
244	Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group. <i>Cancers</i> , 2021, 13, 4910.	1.7	8
245	Therapeutic inhibition of USP9x-mediated Notch signaling in triple-negative breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	29
246	Seeing the forest and the tree: TILs and PD-L1 as immune biomarkers. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 599-606.	1.1	11
247	Oncolytic viruses for triple negative breast cancer and beyond. <i>Biomarker Research</i> , 2021, 9, 71.	2.8	12
248	Breast cancer treatment-related cardiovascular disturbances: advocacy for a watchful attitude in this never-ending story. <i>Expert Opinion on Drug Safety</i> , 2021, , 1-13.	1.0	0
249	The emerging role of immune checkpoint inhibitors for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 531-548.	1.9	16
250	Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer. <i>PLoS ONE</i> , 2021, 16, e0257860.	1.1	4
251	Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 582664.	1.3	11
252	Immunomodulating Therapies in Breast Cancer—From Prognosis to Clinical Practice. <i>Cancers</i> , 2021, 13, 4883.	1.7	15
253	Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence. <i>International Immunopharmacology</i> , 2021, 98, 107876.	1.7	15
254	Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 99, 102257.	3.4	40
255	A review of immune checkpoint blockade in breast cancer. <i>Seminars in Oncology</i> , 2021, 48, 208-225.	0.8	11
256	The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition. <i>Annals of Oncology</i> , 2021, 32, 1236-1244.	0.6	109
257	Integrating single cell sequencing with a spatial quantitative systems pharmacology model spQSP for personalized prediction of triple-negative breast cancer immunotherapy response. <i>Immunoinformatics</i> , 2021, 1-2, 100002.	1.2	18
258	The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2021, 41, 101134.	3.2	147
259	Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIRO2-BREAST IMMUNO trial. <i>Nature Medicine</i> , 2021, 27, 250-255.	15.2	85
260	Quiescent Cancer Cells Resist T Cell Attack by Forming an Immunosuppressive Niche. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2



#	ARTICLE	IF	CITATIONS
261	Great Strides in Precision Medicine: Personalized Oncology, Immunotherapies, and Molecular Diagnostics. , 2021, , 141-417.		0
262	Spatiotemporal Changes in Checkpoint Molecule Expression. Advances in Experimental Medicine and Biology, 2020, 1248, 167-200.	0.8	5
263	Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer. Breast Cancer, 2020, 27, 519-526.	1.3	6
264	Tissue-resident memory CD8+ T cells in cancer immunology and immunotherapy. Pharmacological Research, 2020, 159, 104876.	3.1	17
265	Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, 258-264.	0.6	21
266	Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial. , 2020, 8, e000696.		88
267	Preclinical platform for long-term evaluation of immuno-oncology drugs using hCD34+ humanized mouse model. , 2020, 8, e001513.		17
268	Triple-negative breast cancer: recent treatment advances. F1000Research, 2019, 8, 1342.	0.8	152
270	Chloride intracellular channel protein 2: prognostic marker and correlation with PD-1/PD-L1 in breast cancer. Aging, 2020, 12, 17305-17327.	1.4	14
271	Differential gene expression and AKT targeting in triple negative breast cancer. Oncotarget, 2019, 10, 4356-4368.	0.8	14
272	Triple negative breast cancer: special histological types and emerging therapeutic methods. Cancer Biology and Medicine, 2020, 17, 293-306.	1.4	50
273	An overview of immune checkpoint inhibitors in breast cancer. Exploration of Targeted Anti-tumor Therapy, 2020, 1, .	0.5	4
274	Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 452-478.	2.3	848
275	Role of Immunotherapy in Triple-Negative Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 479-489.	2.3	295
276	Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer. Cancers, 2021, 13, 5225.	1.7	8
277	Novel classes of immunotherapy for breast cancer. Breast Cancer Research and Treatment, 2022, 191, 15-29.	1.1	8
278	Neoadjuvant <i>In Situ</i> Immunomodulation Enhances Systemic Antitumor Immunity against Highly Metastatic Tumors. Cancer Research, 2021, 81, 6183-6195.	0.4	9
280	Analysis of Programmed Death-Ligand 1 Expression, Stromal Tumor-Infiltrating Lymphocytes, and Mismatch Repair Deficiency in Invasive Micropapillary Carcinoma of the Breast. Journal of Immunotherapy and Precision Oncology, 2019, 2, 130-136.	0.6	1

#	ARTICLE	IF	CITATIONS
281	Biomarkers for Immune Checkpoint Inhibitors. , 2021, , 449-463.		0
282	The application of immune checkpoint blockade in breast cancer and the emerging role of nanoparticle. Journal of Controlled Release, 2021, 340, 168-187.	4.8	20
283	Overexpression of Programmed Death-Ligand 1 Receptor mRNA as an Independent Negative Prognostic Factor for Triple Negative Breast Cancer. World Journal of Oncology, 2020, 11, 216-222.	0.6	7
284	Prognostic value of programmed cell death ligand-1 expression in breast cancer. Medicine (United Tj ETQq1 1 0.784314 rgB <sub>5</sub> /Overlook	0.4	5
285	A novel gene expression test method of minimizing breast cancer risk in reduced cost and time by improving SVM-RFE gene selection method combined with LASSO. Journal of Integrative Bioinformatics, 2021, 18, 139-153.	1.0	5
286	The Immune Landscape in Women Cancers. Cancer Treatment and Research, 2020, 180, 215-249.	0.2	3
287	Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors. JCO Precision Oncology, 2021, 5, 1625-1638.	1.5	10
288	Local, multimodal intralesional therapy renders distant brain metastases susceptible to PD-L1 blockade in a preclinical model of triple-negative breast cancer. Scientific Reports, 2021, 11, 21992.	1.6	5
289	The Whole View of Therapies for Breast Cancer. , 2020, , .		0
290	CD204-positive macrophages accumulate in breast cancer tumors with high levels of infiltrating lymphocytes and programmed death ligand-1 expression. Oncology Letters, 2021, 21, 36.	0.8	4
291	Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects. Expert Opinion on Investigational Drugs, 2022, 31, 557-565.	1.9	52
292	Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond. Expert Opinion on Investigational Drugs, 2022, 31, 549-555.	1.9	74
293	Parameters of Tumor Microenvironment Determine Effectiveness of Anti-PD-1/PD-L1 Therapy. Biochemistry (Moscow), 2021, 86, 1461-1468.	0.7	2
294	Treatment landscape of triple-negative breast cancer “ expanded options, evolving needs. Nature Reviews Clinical Oncology, 2022, 19, 91-113.	12.5	414
295	Therapeutic Associations Comprising Anti-PD-1/PD-L1 in Breast Cancer: Clinical Challenges and Perspectives. Cancers, 2021, 13, 5999.	1.7	6
296	ĐŸĐ°Ñ€Đ°Đ¼ĐµÑ,Ñ€Ñ: Đ¼Đ,Đ°Ñ€Đ¾Đ¾Đ°Ñ€ÑfĐ¼ĐµĐ½Đ,Ñ•Đ¾Đ¼Đ¼ÑfÑ...Đ¾Đ»Đ, Đ¾Đ¼Đ¼Ñ€ĐµĐ¼ĐµĐ»ÑÑŹÑ, ŐÑ,,Ñ,,ĐµĐ°Ñ,Đ,Đ²Đ		
297	APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell“Mediated Antitumor Immune Responses. Cancer Immunology Research, 2022, 10, 70-86.	1.6	20
298	Novel immune targets for the treatment of triple-negative breast cancer. Expert Opinion on Therapeutic Targets, 2021, 25, 815-834.	1.5	11

#	ARTICLE	IF	CITATIONS
299	Establishment of a tumor immune microenvironment-based molecular classification system of breast cancer for immunotherapy. <i>Aging</i> , 2021, 13, 24313-24338.	1.4	2
300	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2021, 7, 150.	2.3	112
301	Addition of immunotherapy to chemotherapy for metastatic triple-negative breast cancer: A systematic review and meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 168, 103530.	2.0	13
302	Clinical Progress of PD-1/L1 Inhibitors in Breast Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 724424.	1.3	12
303	Immunotherapy toxicity: identification and management. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 1-17.	1.1	24
305	CD204-positive macrophages accumulate in breast cancer tumors with high levels of infiltrating lymphocytes and programmed death ligand-1 expression. <i>Oncology Letters</i> , 2020, 21, 1-1.	0.8	5
306	Final results regarding the addition of dendritic cell vaccines to neoadjuvant chemotherapy in early HER2-negative breast cancer patients: clinical and translational analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110646.	1.4	14
307	Prognostic and predictive factors of eribulin in patients with heavily pre-treated metastatic breast cancer. <i>Medicine (United States)</i> , 2021, 100, e27859.	0.4	1
308	Mammary Tumor-Derived Transplants as Breast Cancer Models to Evaluate Tumor-Immune Interactions and Therapeutic Responses. <i>Cancer Research</i> , 2022, 82, 365-376.	0.4	1
309	Immunotherapy using PD-1/PDL-1 inhibitors in triple-negative breast cancer: a systematic review. <i>Oncology Reviews</i> , 2021, 15, 497.	0.8	8
310	Mapping Intellectual Structures and Research Hotspots of Triple Negative Breast Cancer: A Bibliometric Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 689553.	1.3	17
311	OUP accepted manuscript. <i>Oncologist</i> , 2022, 27, 245-250.	1.9	1
312	Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity. , 2022, 10, e003717.		27
313	Applications of Extracellular Vesicles in Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 451.	1.7	14
314	Systemic treatment for triple negative breast cancer in older patients: A Young International Society of Geriatric Oncology Review Paper. <i>Journal of Geriatric Oncology</i> , 2022, , .	0.5	4
315	Evaluating Mismatch Repair Status to Screen Clinical Advanced Breast Carcinomas for Immunotherapy: Experience From a Large Academic Institution. <i>Clinical Breast Cancer</i> , 2022, , .	1.1	1
316	Molecular Targets of Triple-Negative Breast Cancer: Where Do We Stand?. <i>Cancers</i> , 2022, 14, 482.	1.7	21
317	Developing an immune signature for triple-negative breast cancer to predict prognosis and immune checkpoint inhibitor response. <i>Future Oncology</i> , 2022, 18, 1055-1066.	1.1	3

#	ARTICLE	IF	CITATIONS
318	Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes. <i>Journal of Clinical Oncology</i> , 2022, 40, 1741-1754.	0.8	65
319	Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2022, 104, 102352.	3.4	17
320	A New Standard of Care: Pembrolizumab in Programmed Death-ligand 1 Positive, Metastatic, Triple-negative Breast Cancer. <i>Touch Reviews in Oncology &amp; Haematology</i> , 2021, 17, 60.	0.1	0
321	Emerging treatment strategies for metastatic triple-negative breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210869.	1.4	15
322	Tumor Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Human Breast Cancer Are Mediated by PD-L1-S283 and Chemokine Axes. <i>Cancers</i> , 2022, 14, 1042.	1.7	7
323	Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy. <i>Frontiers in Oncology</i> , 2022, 12, 802579.	1.3	5
324	Emerging strategies for TNBC with early clinical data: new chemoimmunotherapy strategies. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 21-35.	1.1	4
325	Current Treatment and Future Trends of Immunotherapy in Breast Cancer. <i>Current Cancer Drug Targets</i> , 2022, 22, 667-677.	0.8	5
326	Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 567-591.	1.9	29
327	CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 593-605.	1.9	31
328	Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy. <i>Molecular Biomedicine</i> , 2022, 3, 8.	1.7	38
329	Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers. <i>ESMO Open</i> , 2022, 7, 100419.	2.0	7
330	Inhibitor of glutamine metabolism V9302 promotes ROS-induced autophagic degradation of B7H3 to enhance antitumor immunity. <i>Journal of Biological Chemistry</i> , 2022, 298, 101753.	1.6	19
331	Polysome-mediated cytosolic delivery of cyclic dinucleotide STING agonist enhances tumor immunotherapy. <i>Bioactive Materials</i> , 2022, 16, 1-11.	8.6	26
332	Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Breast Cancer: Looking beyond Tumoral PD-L1. <i>Biomedicines</i> , 2021, 9, 1863.	1.4	10
333	Immune Milieu and Genomic Alterations Set the Triple-Negative Breast Cancer Immunomodulatory Subtype Tumor Behavior. <i>Cancers</i> , 2021, 13, 6256.	1.7	6
334	Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges. <i>Cancers</i> , 2022, 14, 109.	1.7	21
335	Current Photoactive Molecules for Targeted Therapy of Triple-Negative Breast Cancer. <i>Molecules</i> , 2021, 26, 7654.	1.7	11

#	ARTICLE	IF	CITATIONS
336	Laser activatable nanographene colloids for chemo-photothermal combined gene therapy of triple-negative breast cancer. <i>Materials Science and Engineering C</i> , 2022, 133, 112605.	3.8	16
337	Informatics in Medical Product Regulation: The Right Drug at the Right Dose for the Right Patient. <i>Methods in Molecular Biology</i> , 2022, 2486, 277-314.	0.4	0
338	Immunotherapy in triple-negative breast cancer: A literature review and new advances. <i>World Journal of Clinical Oncology</i> , 2022, 13, 219-236.	0.9	16
339	Electrolyte Abnormalities Associated With The Use of Atezolizumab – A Systematic Review. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2022, 12, 35-44.	0.4	1
340	Investigating the Prognostic Relevance of Tumor Immune Microenvironment and Immune Gene Assembly in Breast Carcinoma Subtypes. <i>Cancers</i> , 2022, 14, 1942.	1.7	2
348	Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2807-2817.	3.2	30
349	Immune Checkpoint Inhibitors in the Treatment of Breast Cancer Brain Metastases. <i>Oncologist</i> , 2022, 27, 538-547.	1.9	4
350	The interplay of immunotherapy, chemotherapy, and targeted therapy in tripple negative breast cancer (TNBC). , 2022, , 149-176.		5
351	Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2022, 34, 117-130.	0.7	2
352	Identification of Cancer-Associated Fibroblast Subtype of Triple-Negative Breast Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-14.	0.6	8
353	PIECEWISE FRACTIONAL-ORDER MODELING OF THE BREAST CANCER EPIDEMIOLOGY AFTER THE ATEZOLIZUMAB TREATMENT. <i>Fractals</i> , 2022, 30, .	1.8	4
354	Immune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice. <i>Cancers</i> , 2022, 14, 2102.	1.7	12
355	Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward. <i>Medicina (Lithuania)</i> , 2022, 58, 600.	0.8	1
356	Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	9
357	Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives. <i>Cancers</i> , 2022, 14, 2136.	1.7	21
358	Potential epigenetic modifications implicated in triple- to quadruple-negative breast cancer transition: a review. <i>Epigenomics</i> , 2022, , .	1.0	7
359	Immune Checkpoint Blockades in Triple-Negative Breast Cancer: Current State and Molecular Mechanisms of Resistance. <i>Biomedicines</i> , 2022, 10, 1130.	1.4	11
360	Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer. <i>Laboratory Investigation</i> , 2022, 102, 1143-1149.	1.7	5

#	ARTICLE	IF	CITATIONS
361	A novel four-gene signature predicts immunotherapy response of patients with different cancers. <i>Journal of Clinical Laboratory Analysis</i> , 2022, , e24494.	0.9	2
362	Role of radiomics in predicting immunotherapy response. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 575-591.	0.9	10
363	Therapeutic pattern and progress of neoadjuvant treatment for triple-negative breast cancer (Review). <i>Oncology Letters</i> , 2022, 24, .	0.8	4
364	Nanodrugs Targeting T Cells in Tumor Therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
366	Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492210998.	0.6	10
367	Update on prognostic and predictive biomarkers of breast cancer. <i>Seminars in Diagnostic Pathology</i> , 2022, 39, 322-332.	1.0	20
368	Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis. <i>Cells</i> , 2022, 11, 1857.	1.8	10
369	Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	4
370	Breast Cancer Metastasis: Mechanisms and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6806.	1.8	74
371	SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 3042.	1.7	1
372	Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 529-540.	21.5	134
373	Prognostic Significance of Lymphocyte Infiltrate Localization in Triple-Negative Breast Cancer. <i>Journal of Personalized Medicine</i> , 2022, 12, 941.	1.1	3
374	Heterogeneity of triple-negative breast cancer: understanding the Daedalian labyrinth and how it could reveal new drug targets. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 557-573.	1.5	5
375	Treatment-Related Adverse Events of PD-1 or PD-L1 Inhibitors for Triple Negative Breast Cancer Patients: A Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
376	Prognostic/predictive markers in systemic therapy resistance and metastasis in breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211126.	1.4	3
377	A Novel YTHDF3-Based Model to Predict Prognosis and Therapeutic Response in Breast Cancer. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	4
378	Research progress on immunotherapy in triple-negative breast cancer (Review). <i>International Journal of Oncology</i> , 2022, 61, .	1.4	9
379	Predictive biomarkers for personalized medicine in breast cancer. <i>Cancer Letters</i> , 2022, 545, 215828.	3.2	14

#	ARTICLE	IF	CITATIONS
380	CCDC69 is a prognostic marker of breast cancer and correlates with tumor immune cell infiltration. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	6
381	Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. <i>JCO Precision Oncology</i> , 2022, , .	1.5	11
382	Immunotherapy and breast cancer: an overview. <i>Current Opinion in Oncology</i> , 2022, 34, 587-594.	1.1	13
383	Clinical trials of immunotherapy in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 195, 1-15.	1.1	19
384	Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancer. <i>IScience</i> , 2022, 25, 104702.	1.9	15
385	Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
386	An Overview of Breast Cancer Therapy. , 2022, , 242-258.		0
387	Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 387, 217-226.	13.9	266
388	A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and <i>In Situ</i> Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 4392-4401.	3.2	13
389	Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 3860.	1.7	11
390	Live Biotherapeutic <i>Lactococcus lactis</i> GEN3013 Enhances Antitumor Efficacy of Cancer Treatment via Modulation of Cancer Progression and Immune System. <i>Cancers</i> , 2022, 14, 4083.	1.7	7
391	Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8878.	1.8	5
392	Cancer Immunotherapy and Delivery System: An Update. <i>Pharmaceutics</i> , 2022, 14, 1630.	2.0	12
393	Phase 1b clinical trial of pucotenlimab (HX008), a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
394	Comparative Efficacy and safety of new targeted therapies and immunotherapies for metastatic triple negative breast cancer: a network meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2023, 22, 243-252.	1.0	1
395	Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	17
396	Prognostic and predictive biomarkers with therapeutic targets in breast cancer: A 2022 update on current developments, evidence, and recommendations. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 1343-1360.	0.5	3
397	Tumor infiltrating lymphocytes (TILs) as a predictive biomarker of response to checkpoint blockers in solid tumors: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 177, 103773.	2.0	18



#	ARTICLE	IF	CITATIONS
398	Intratumoral xenogeneic tissue-specific cell immunotherapy inhibits tumor growth by increasing antitumor immunity in murine triple negative breast and pancreatic tumor models. <i>Cancer Letters</i> , 2022, 545, 115478.	3.2	8
399	SNAI1-dependent upregulation of CD73 increases extracellular adenosine release to mediate immune suppression in TNBC. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
400	Oligometastatic breast cancer: Dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability?. <i>Cancer Treatment Reviews</i> , 2022, 110, 102462.	3.4	6
401	Recent advances in therapeutic strategies for triple-negative breast cancer. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	145
402	Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	5
403	Consistent expression of PD-L1 in tumor microenvironment with peripheral PD-1/PD-L1 in circulating T lymphocytes of operable breast cancer: a diagnostic test. <i>Diagnostic Pathology</i> , 2022, 17, .	0.9	6
404	Thyroid-related adverse events induced by immune checkpoint inhibitors. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	9
405	Current landscape of personalized clinical treatments for triple-negative breast cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	11
406	TIMM8A is associated with dysfunction of immune cell in BRCA and UCEC for predicting anti-PD-L1 therapy efficacy. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	2
407	<i>Cancer Immunotherapy Clinical Trials</i> . , 2022, , 1-24.		0
408	Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2023, 7, 1488-1495.	2.5	7
409	Immune checkpoint inhibition in early-stage triple-negative breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 1225-1238.	1.1	2
410	Atezolizumab plus nab-paclitaxel for unresectable, locally advanced or metastatic breast cancer: real-world results from a single academic center in Austria. <i>BMC Cancer</i> , 2022, 22, .	1.1	4
411	Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer. <i>Current Oncology Reports</i> , 2022, 24, 1801-1819.	1.8	7
412	Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer. , 2022, 10, e005119.		8
413	Immune Checkpoint Inhibitors and Other Immune Therapies in Breast Cancer: A New Paradigm for Prolonged Adjuvant Immunotherapy. <i>Biomedicines</i> , 2022, 10, 2511.	1.4	10
414	Current Therapeutic Strategies for Metastatic Triple-Negative Breast Cancer: From Pharmacistsâ€™ Perspective. <i>Journal of Clinical Medicine</i> , 2022, 11, 6021.	1.0	2
415	Strong prognostic value of SLAMF7 protein expression in patients with lymph nodeâ€™positive breast cancer. <i>Oncology Letters</i> , 2022, 24, .	0.8	2

#	ARTICLE	IF	CITATIONS
417	Improvement of TNBC immune checkpoint blockade with a microwave-controlled ozone release nanosystem. <i>Journal of Controlled Release</i> , 2022, 351, 954-969.	4.8	3
418	Nanomedicine for advanced cancer immunotherapy. <i>Journal of Controlled Release</i> , 2022, 351, 1017-1037.	4.8	7
419	Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2023, 197, 51-56.	1.1	3
420	Recent advances in atezolizumab-based programmed death-ligand 1 (PD-L1) blockade therapy for breast cancer. <i>International Immunopharmacology</i> , 2022, 113, 109334.	1.7	6
421	Surface-engineered nanoparticles in cancer immune response and immunotherapy: Current status and future prospects. <i>Biomedicine and Pharmacotherapy</i> , 2023, 157, 113998.	2.5	5
422	The effect of organ-specific tumor microenvironments on response patterns to immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
423	Efficacy and Safety of Immune Checkpoint Inhibitors in Triple-negative Breast Cancer: A Study Based on 41 Cohorts Incorporating 6558 Participants. <i>Journal of Immunotherapy</i> , 0, Publish Ahead of Print, .	1.2	0
424	Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety. <i>BMC Cancer</i> , 2022, 22, .	1.1	6
425	Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking. <i>International Immunopharmacology</i> , 2022, 113, 109444.	1.7	6
426	â€œWhy is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical researchâ€™. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 1291-1310.	1.9	2
427	Role of Immunotherapy in Early- and Late-Stage Triple-Negative Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2023, 37, 133-150.	0.9	2
428	Genetic Heterogeneity, Tumor Microenvironment and Immunotherapy in Triple-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14937.	1.8	21
429	Role of Immunotherapy in the Treatment of Triple-Negative Breast Cancer: A Literature Review. <i>Cureus</i> , 2022, , .	0.2	1
430	Role of Surgical Pathologist for Detection of Predictive Immuno-oncological Factors in Breast Cancer. <i>Advances in Anatomic Pathology</i> , 0, Publish Ahead of Print, .	2.4	2
431	Manganese-enriched photonic/catalytic nanomedicine augments synergistic anti-TNBC photothermal/nanocatalytic/immuno-therapy via activating cGAS-STING pathway. <i>Biomaterials</i> , 2023, 293, 121988.	5.7	16
433	Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
434	Identification of HMGA2 as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1

#	ARTICLE	IF	CITATIONS
435	Radiomic models based on magnetic resonance imaging predict the spatial distribution of CD8+ tumor-infiltrating lymphocytes in breast cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
436	Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80. <i>Nature Cancer</i> , 2022, 3, 1513-1533.	5.7	20
437	Role of Immunotherapy in Breast Cancer. <i>JCO Oncology Practice</i> , 2023, 19, 167-179.	1.4	19
438	Molecular Imaging of Oxygenation Changes during Immunotherapy in Combination with Paclitaxel in Triple Negative Breast Cancer. <i>Biomedicines</i> , 2023, 11, 125.	1.4	4
439	CD8+ TĀcell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. <i>Cell Reports Medicine</i> , 2023, 4, 100878.	3.3	24
440	Immunotherapy: Review of the Existing Evidence and Challenges in Breast Cancer. <i>Cancers</i> , 2023, 15, 563.	1.7	2
441	Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome. <i>Cancers</i> , 2023, 15, 321.	1.7	21
442	Spontaneous, naturally occurring cancers in non-human primates as a translational model for cancer immunotherapy. , 2023, 11, e005514.		7
443	Theranostics for Triple-Negative Breast Cancer. <i>Diagnostics</i> , 2023, 13, 272.	1.3	7
444	Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review. <i>Cancer Treatment Reviews</i> , 2023, 114, 102511.	3.4	4
445	Targeting Notch-Driven Cytokine Secretion: Novel Therapies for Triple Negative Breast Cancer. <i>DNA and Cell Biology</i> , 2023, 42, 73-81.	0.9	2
446	Improved Targeting of Therapeutics by Nanocarrier-Based Delivery in Cancer Immunotherapy and Their Future Perspectives. <i>BioNanoScience</i> , 2023, 13, 278-299.	1.5	1
447	Tumor immunology. , 2023, , 245-452.		0
448	Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges. <i>Journal of Clinical Medicine</i> , 2023, 12, 953.	1.0	12
449	Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers. , 2023, 11, e003837.		2
450	Immunotherapy and tumor mutational burden in cancer patients with liver metastases: A meta and real word cohort analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
451	Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low. <i>Breast Cancer Research</i> , 2023, 25, .	2.2	6
452	Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases. <i>ESMO Open</i> , 2023, 8, 100884.	2.0	6

#	ARTICLE	IF	CITATIONS
453	Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer. <i>Breast</i> , 2023, 69, 330-341.	0.9	3
454	Immune checkpoint inhibition: a future guided by radiology. <i>British Journal of Radiology</i> , 0, , .	1.0	1
455	Novel roles of RNA-binding proteins in drug resistance of breast cancer: from molecular biology to targeting therapeutics. <i>Cell Death Discovery</i> , 2023, 9, .	2.0	6
456	Immunotherapy in breast cancer: an overview of current strategies and perspectives. <i>Npj Breast Cancer</i> , 2023, 9, .	2.3	63
457	Critical Review on the Different Roles of Exosomes in TNBC and Exosomal-Mediated Delivery of microRNA/siRNA/lncRNA and Drug Targeting Signalling Pathways in Triple-Negative Breast Cancer. <i>Molecules</i> , 2023, 28, 1802.	1.7	2
458	Efficacy of PARP Inhibitor, Platinum, and Immunotherapy in BRCA-Mutated HER2-Negative Breast Cancer Patients: A Systematic Review and Network Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2023, 12, 1588.	1.0	1
459	The role of immune checkpoint inhibitors in patients with intracranial metastatic disease. <i>Journal of Neuro-Oncology</i> , 2023, 161, 469-478.	1.4	0
460	Cardiotoxicity from neoadjuvant targeted treatment for breast cancer prior to surgery. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	1
461	Novel diagnostic biomarkers of T cell-mediated tumor killing characteristics for early-stage triple negative breast cancer: A SEER analysis and molecular portraits. <i>Medicine (United States)</i> , 2023, 102, e33059.	0.4	0
462	Variable Intrinsic Expression of Immunoregulatory Biomarkers in Breast Cancer Cell Lines, Mammospheres, and Co-Cultures. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4478.	1.8	2
463	PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	7
464	Status and prognostic value of immunological biomarkers of breast cancer. <i>Oncology Letters</i> , 2023, 25, .	0.8	1
465	Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer. <i>Journal of Personalized Medicine</i> , 2023, 13, 526.	1.1	5
466	Inflammation, Infiltration, and Evasion—Tumor Promotion in the Aging Breast. <i>Cancers</i> , 2023, 15, 1836.	1.7	2
467	The prognostic value of tumour-infiltrating lymphocytes, programmed cell death protein-1 and programmed cell death ligand-1 in Stage III triple-negative breast cancer. <i>British Journal of Cancer</i> , 2023, 128, 2044-2053.	2.9	3
468	Surgical Management of Pancreatic Neuroendocrine Tumors. <i>Cancers</i> , 2023, 15, 2006.	1.7	3
469	Involvement of the kynurenine pathway in breast cancer: updates on clinical research and trials. <i>British Journal of Cancer</i> , 2023, 129, 185-203.	2.9	6
470	Hedgehog Signaling Regulates Treg to Th17 Conversion Through Metabolic Rewiring in Breast Cancer. <i>Cancer Immunology Research</i> , 2023, 11, 687-702.	1.6	7

#	ARTICLE	IF	CITATIONS
471	High VISTA expression is linked to a potent epithelial-mesenchymal transition and is positively correlated with PD1 in breast cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
472	Clonogenicity-based radioresistance determines the expression of immune suppressive immune checkpoint molecules after hypofractionated irradiation of MDA-MB-231 triple-negative breast cancer cells. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
473	Immunotherapy for Metastatic Triple Negative Breast Cancer: Current Paradigm and Future Approaches. <i>Current Treatment Options in Oncology</i> , 2023, 24, 628-643.	1.3	15
474	The regulation of the programmed death ligand 1 (PD-L1) by nitric oxide in breast cancer: Immunotherapeutic implication. , 2023, , 173-192.		0
540	Immune-Checkpoint Inhibitors: A New Line of Attack in Triple-Negative Breast Cancer. <i>Cancer Treatment and Research</i> , 2023, , 29-62.	0.2	0